Skip to content
Head to head

Hims & Hers Health vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: HIMS · TAK

Updated moments ago

1-year performance, rebased to 100

HIMS -59.0%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
HIMSTAK
Snapshot
Sector----
Last price14.6021.77
Change today-8.86%+1.68%
1-year return-56.6%+57.5%
Market cap$3.42B$69.76B
52-week range13.74 – 40.9913.92 – 22.07
Valuation
P/E (TTM)-17.59311.00
P/E percentile, own 5-yr range39th100th
P/B9.631.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.51-0.30
Net profit (TTM)$119.55M$-970.94M
Revenue (TTM)$2.87B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+48.6%+6.7%
Gross margin63.8%65.8%
Operating margin-8.1%14.3%
Net margin-6.7%0.9%
Free cash flow (TTM)$8.24M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership69.3%51.3%
Insider activity (12mo)25 buy / 25 sell19 buy / 31 sell
Short interest (% of float)22.1%0.1%
Analyst consensus25% buy / 75% hold (12)100% buy (1)
Analyst price target$29 (+100%)$50 (+132%)
StockVane view
StockVane Quant RatingE (4)C (90)
Company
Employees2,44247,029
Founded20171781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.